NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection

Background. Daclatasvir is an NS5A inhibitor approved for treatment of infection due to hepatitis C virus (HCV) genotypes (GTs) 1–4. To support daclatasvir use in HCV genotype 4 infection, we examined a diverse genotype 4–infected population for HCV genotype 4 subtype prevalence, NS5A polymorphisms...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Infect Dis
Autors principals: Zhou, Nannan, Hernandez, Dennis, Ueland, Joseph, Yang, Xiaoyan, Yu, Fei, Sims, Karen, Yin, Philip D., McPhee, Fiona
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2016
Matèries:
Major Articles and Brief Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4690147/
https://ncbi.nlm.nih.gov/pubmed/26170396
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiv379
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars